Search
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … and a reduction in electrical nerve impulses.
Categories: Human Immunoglobulin GProducts: Vyvgart ScDesipramine
go.drugbank.com/drugs/DB01151ApprovedDesipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. … TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsSynonyms: 5-(γ-methylaminopropyl)iminodibenzyl, N-(3-methylaminopropyl)iminobibenzylBezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acidInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalInsulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersZopiclone
go.drugbank.com/drugs/DB01198ApprovedInvestigationalZopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylateDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalDenosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of … It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.
Products: XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsMethoxy polyethylene glycol-epoetin beta
go.drugbank.com/drugs/DB09107ApprovedInvestigationalMethoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. … ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Categories: Compounds used in a research, industrial, or household settingProducts: MIRCERA 360 MCG/0.6 ML SC/IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET, MIRCERA 100 MCG/ML SC/IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETPicric acid
go.drugbank.com/drugs/DB03651ApprovedUsed as antiseptic, astringent, and stimulant for epitheliazation.
Categories: Compounds used in a research, industrial, or household settingProducts: San SuAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, alveolar soft part sarcoma, muscle … [L146011] It is the first approved immunotherapy-based adjuvant regimen for Stage III dMMR colon cancer.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: Tecentriq Sc, TECENTRIQ SC